Related Experiment Video
Updated: Jul 16, 2025

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve
Published on: June 14, 2017
Insight into the underlying molecular mechanism of dilated cardiomyopathy through integrative analysis of data
Hongli Xiong1, Zhe Zheng2, Congcong Zhao1
1Department of Forensic Medicine, Faculty of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.
Insights
Dilated cardiomyopathy (DCM) involves complex molecular mechanisms. This study identified key pathways like the TCA cycle and oxidative phosphorylation as crucial in DCM development.
Area of Science:
- Cardiology
- Molecular Biology
- Proteomics
Background:
- Dilated cardiomyopathy (DCM) is a prevalent global condition causing ventricular dysfunction and heart failure.
- Limited understanding of DCM's molecular basis hinders effective treatment strategies.
- This study investigates the molecular underpinnings of DCM.
Purpose of the Study:
- To explore the molecular mechanisms of dilated cardiomyopathy.
- To identify key genes and proteins involved in DCM pathogenesis.
- To elucidate the role of specific metabolic and contractile pathways in DCM.
Main Methods:
- Integrative analysis combining data mining, iTRAQ-PRM proteomics, and bioinformatics.
- DCM induced in a rat model using doxorubicin treatment.
- Identification and association analysis of differentially expressed proteins (DEPs) with known DCM target genes.
Main Results:
- Identified 935 key target genes and 782 DEPs (348 up-regulated, 434 down-regulated) in myocardial tissue.
- Functional annotation revealed involvement of the TCA cycle, oxidative phosphorylation, and cardiac muscle contraction.
- Association analysis confirmed the significance of these pathways in DCM.
Conclusions:
- The tricarboxylic acid (TCA) cycle is a critical pathway in DCM.
- Oxidative phosphorylation plays a significant role in the molecular mechanisms of DCM.
- Cardiac muscle contraction is implicated in the pathogenesis of dilated cardiomyopathy.
Background:
DCM is a common cardiomyopathy worldwide, which is characterized by ventricular dilatation and systolic dysfunction. DCM is one of the most widespread diseases contributing to sudden death and heart failure. However, our understanding of its molecular mechanisms is limited because of its etiology and underlying mechanisms. Hence, this study explored the underlying molecular mechanism of dilated cardiomyopathy through integrative analysis of data mining, iTRAQ-PRM proteomics and bioinformatics METHODS: DCM target genes were downloaded from the public databases. Next, DCM was induced in 20 rats by 8 weeks doxorubicin treatment (2.5 mg/kg/week). We applied isobaric tags for a relative and absolute quantification (iTRAQ) coupled with proteomics approach to identify differentially expressed proteins (DEPs) in myocardial tissue. After association analysis of the DEPs and the key target genes, subsequent analyses, including functional annotation, pathway enrichment, validation, were performed.
Results:
Nine hundred thirty-five genes were identified as key target genes from public databases. Meanwhile, a total of 782 DEPs, including 348 up-regulated and 434 down-regulated proteins, were identified in our animal experiment. The functional annotation of these DEPs revealed complicated molecular mechanisms including TCA cycle, Oxidative phosphorylation, Cardiac muscle contraction. Moreover, the DEPs were analyzed for association with the key target genes screened in the public dataset. We further determined the importance of these three pathways.
Conclusion:
Our results demonstrate that TCA cycle, Oxidative phosphorylation, Cardiac muscle contraction played important roles in the detailed molecular mechanisms of DCM.
Related Concept Videos
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

